A Phase II Trial of Irinotecan (CPT-11), 5-Fluorouracil (5-FU), Glutamine, Leucovorin and Celecoxib as First Line Therapy for Metastatic Colorectal Cancer –GI00-2

Abstracts/Posters/Presentations:

• Christopher Sweeney MD, David Seitz MD, Rafat Ansari MD, William Pletcher MD, Naveed Chowhan MD, Jake Vinson MHA, Cindy Stoner BS; Patrick Loehrer MD;
  A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer: A Hoosier Oncology Group Study GI00-2. Accepted to the ASCO annual meeting May 18-21, 2002, Orlando, FL
• Chong-Xian Pan MD, Patrick Loehrer MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, Christopher Sweeney MD. A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer (CRC): A Hoosier Oncology Group Study GI00-2. Accepted to the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• Chong-Xian Pan MD, Patrick Loehrer MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, Christopher Sweeney MD. A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer (CRC): A Hoosier Oncology Group Study GI00-2. Presented at the Glaxo/Smithkline National Oncology Fellows Forum, February 28-March 2, 2003, Miami, FL.

Manuscripts/Articles:

• Chong-Xian Pan MD, Ph.D, Patrick Loehrer MD, David Seitz MD, Paul Helft MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, and Christopher Sweeney MD. A Phase II Trial of Irinotecan, 5-Fluorouracil, Leucovorin, combined with Celecoxib and Glutamine as first line therapy for advanced colorectal cancer: Hoosier Oncology Group GI00-2. Oncology 2005;69:63-70. See abstract.